灵康药业集团股份有限公司 2025年年度业绩预告

Group 1 - The company expects a net profit attributable to shareholders of approximately -127 million yuan for the year 2025, representing a reduction in losses of about 2.88% compared to the previous year [2][4] - The expected operating revenue for 2025 is around 365 million yuan, which is a decrease of approximately 3.89% year-on-year [4] - The main reasons for the anticipated losses include the inability of sales gross profit to cover operating expenses, intensified market competition due to ongoing drug procurement policies, and a significant decline in sales revenue from certain product categories [7] Group 2 - The company reported a net profit attributable to shareholders of -130.76 million yuan for the previous year, with a total profit of -127.73 million yuan [6] - The previous year's operating revenue was 379.78 million yuan, with a loss per share of -0.18 yuan [6] - The company is expanding its pharmaceutical agency and distribution business, which has seen significant revenue growth compared to the previous year [7] Group 3 - The company has issued convertible bonds with a total amount of 525 million yuan, and the current conversion price is 6.50 yuan per share [12][14] - If the stock price remains below 85% of the conversion price for a specified period, it may trigger a downward adjustment of the conversion price [12][17] - The company will hold a board meeting to decide on any adjustments to the conversion price if the conditions are met [17]